WuXi XDC Cayman (FRA:L74) Capex-to-Revenue : 0.26 (As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

WuXi XDC Cayman's Capital Expenditure for the three months ended in Jun. 2023 was €-17.24 Mil. Its Revenue for the three months ended in Jun. 2023 was €65.20 Mil.

Hence, WuXi XDC Cayman's Capex-to-Revenue for the three months ended in Jun. 2023 was 0.26.

WuXi XDC Cayman Capex-to-Revenue Historical Data

The historical data trend for WuXi XDC Cayman's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman Capex-to-Revenue Chart

WuXi XDC Cayman Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Revenue

0.55

0.17

0.20

0.25

WuXi XDC Cayman Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23
Capex-to-Revenue	Get a 7-Day Free Trial			0.05	-	0.25	0.26	-

Competitive Comparison of WuXi XDC Cayman's Capex-to-Revenue

For the Diagnostics & Research subindustry, WuXi XDC Cayman's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi XDC Cayman's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where WuXi XDC Cayman's Capex-to-Revenue falls into.

WuXi XDC Cayman Capex-to-Revenue Calculation

WuXi XDC Cayman's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-69.269)	/	272.76
	=	0.25

WuXi XDC Cayman's Capex-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Capex-to-Revenue	=	- Capital Expenditure	/	Revenue
	=	- (-17.237)	/	65.2
	=	0.26

WuXi XDC Cayman (FRA:L74) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

WuXi XDC Cayman Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (FRA:L74) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » Capex-to-Revenue

Comparable Companies

Traded in Other Exchanges

02268:Hong Kong

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines